Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 10/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | HNF4A | P41235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846268 | 0.86 | RXRA (0.36) | RARGRARARARBRXRAHNF4A | |
| SCHEMBL6033027 | 0.80 | RARG (0.43) | RARGRARARARB | |
| SCHEMBL6528402 | 0.80 | RARG (0.46) | RARGRARARARBPPARGRXRA | |
| SCHEMBL5364822 | 0.77 | RXRA (0.48) | RARGRARARARBL3MBTL1ALDH1A1 | |
| SCHEMBL8005483 | 0.77 | RXRA (0.50) | RARGRARARARBL3MBTL1ALDH1A1 | |
| SCHEMBL15367718 | 0.76 | RARG (0.40) | RARGRARARARBPPARGRXRA | |
| SCHEMBL6033474 | 0.76 | RXRA (0.32) | PPARGRXRAHNF4ACYP26A1 | |
| SCHEMBL6479338 | 0.75 | RXRA (0.47) | RARGRARARARBALDH1A1PPARG | |
| SCHEMBL5366510 | 0.74 | RXRA (0.45) | RARGRARARARBL3MBTL1RXRA | |
| SCHEMBL6560607 | 0.74 | RXRA (0.38) | RARGRARARARBPPARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | disclosed |
| US-6313162-B1 | FOR USE IN HUMAN OR VETERINARY MEDICINE SUCH AS DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHHALMOLOGICAL DISORDERS; AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) GALDERMA (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1086080-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2001-03-28 | — | — | EP | disclosed |
| US-6046220-A | ADMINISTERING TO THE PATIENT A PROPYNYL OR DIENYL BIAROMATIC COMPOUND TO TREAT A SKIN DISORDER, INFLAMMATORY CONDITIONS, VISION DEFECTS, ALOPECIA, CARDIOVASCULAR DISORDER, CANCER OR PRECANCER AND INSULIN DEPENDANT DIABETES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-04-04 | — | — | US | disclosed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | RARG 2050/4885RARA 2083/4885RARB 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.